BOCOM International Holdings Company analyst maintained a Buy rating on Sino Biopharmaceutical yesterday and set a price target of HK$7.70. The company’s shares closed last Thursday at HK$5.19.TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Sino Biopharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of HK$8.54.
Based on Sino Biopharmaceutical’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of HK$7.13 billion and a GAAP net loss of HK$522.62 million. In comparison, last year the company earned a revenue of HK$6.5 billion and had a net profit of HK$241.34 million
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SBMFF in relation to earlier this year.
